Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.64
+0.06000.91%
Volume:287.03K
Turnover:1.90M
Market Cap:453.19M
PE:-3.25
High:6.79
Open:6.33
Low:6.25
Close:6.58
Loading ...

EyePoint Pharmaceuticals Shares up 25% After Co Reports Interim Mid-Stage Data for Experimental Eye Disease Drug

THOMSON REUTERS
·
28 Oct 2024

BRIEF-Eyepoint Pharmaceuticals Announces Positive Interim 16-Week Data For Ongoing Phase 2 Verona Clinical Trial Of Duravyu For Diabetic Macular Edema

Reuters
·
28 Oct 2024

EyePoint announces interim 16-week data for ongoing Phase 2 VERONA trial

TIPRANKS
·
28 Oct 2024

EyePoint Pharmaceuticals Inc - Full Topline Data Expected in Q1 2025

THOMSON REUTERS
·
28 Oct 2024

EyePoint Pharmaceuticals Inc: Favorable Safety Profile Continues With No Duravyu-Related Ocular or Systemic Saes to Date

THOMSON REUTERS
·
28 Oct 2024

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 Verona Clinical Trial of Duravyu™ for Diabetic Macular Edema

THOMSON REUTERS
·
28 Oct 2024

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

GlobeNewswire
·
28 Oct 2024

Positive Outlook for EyePoint Pharmaceuticals Amid Promising Phase 3 Trials for Duravyu

TIPRANKS
·
25 Oct 2024

EyePoint Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Oct 2024

Positive Outlook for EyePoint Pharmaceuticals: Phase 3 LUGANO Trial for DURAVYU Boosts Buy Rating

TIPRANKS
·
25 Oct 2024

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 Lugano Clinical Trial of Duravyutm for the Treatment of Wet Age-Related Macular Degeneration

THOMSON REUTERS
·
24 Oct 2024

EyePoint Pharmaceuticals Inc - Topline Data From Phase 3 Trials Expected in 2026

THOMSON REUTERS
·
24 Oct 2024

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

GlobeNewswire
·
24 Oct 2024

EyePoint Pharmaceuticals Initiated at Sector Outperform by Scotiabank

Dow Jones
·
16 Oct 2024

Scotiabank Initiates EyePoint Pharmaceuticals at Sector Outperform With $18 Price Target

MT Newswires Live
·
16 Oct 2024

EyePoint initiated with an Outperform at Scotiabank

TIPRANKS
·
16 Oct 2024